Medizinische Fakultät Mannheim, Universität Heidelberg

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma	IDH1-mutant Glioma; IDH2-mutant Glioma	Active, not recruiting	Phase 1 / Phase 2	2026-07-08		NCT06478212

Clinical trials